Sponsorship

By choosing to sponsor the 21st CIMT Annual Meeting, you are not merely supporting an event; you are propelling the future of cancer immunotherapy research and development in Europe and beyond.

As a non-profit organization, CIMT is deeply committed to fostering development and translation of cancer immunotherapies, and we genuinely cannot achieve our mission without the invaluable support from our sponsors. Align your organization with scientific excellence and innovation – sponsor the 21st CIMT Annual Meeting and become a crucial stakeholder in shaping the future of cancer immunotherapy.

For more information on how to become a sponsor of the 21st CIMT Annual Meeting, please download our Information for Sponsors and Exhibitors.




In 2023, the CIMT Annual Meeting was supported by the following industry leaders:
No items found.

Sponsorship Opportunities

Support our mission by becoming a sponsor. Gain access and visibility by participating in Europe’s leading communications and networking platform for cancer immunotherapy.

CIMT brings together leading international experts and hosts dedicated working groups on immune monitoring, drug development policies and the rapid translation of scientific knowledge into drug development.

CIMT connects the global cancer immunotherapy community in the heart of Europe. The CIMT Annual Meeting in Mainz, Germany, brings together over 900 international participants for high-level scientific exchange, collaboration and education focused on cancer immunotherapy.

Purchase one of our sponsorship packages or participate in our Annual Meeting as an industry exhibitor. With an annual sponsorship, you will help support CIMT’s educational objectives and scientific initiatives. In return, CIMT will give you numerous benefits, such as customized satellite symposia, company promotion, exhibit booth, and complimentary tickets.

For more information, please contact office[at]cimt.eu

Subscribe to the CIMT newsletter

Stay up to date on Europe’s largest meeting focused on cancer immunotherapy research and development